Demonstration of antibodies against human malignant melanoma by immunofluorescence.

No abstract is available for this paper.

• Publication year

  1968

• Venue

  Surgery

• Publication date

  1968-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 4173159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures.

  1967cited by this paper
• Specific antigens of tumors and leukemias of experimental animals.

  1966cited by this paper
• Tumor antigens.

  1966cited by this paper
• Clinical immunologic study of malignant disease: response to tumor transplants and transfer of leukocytes.

  1966cited by this paper
• DEMONSTRATION OF MOUSE ISOANTIGENS AT THE CELLULAR LEVEL BY THE FLUORESCENT ANTIBODY TECHNIQUE

  1961cited by this paper
• Spontaneous regression of human melanoma. Clinical and experimental studies

  1960cited by this paper

• State of Melanoma: An Historic Overview of a Field in Transition.

  2021cites this paper
• Melanoma of Unknown Primary

  2018cites this paper
• Therapeutic Cancer Vaccines for Melanoma

  2018cites this paper
• Do melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary?

  2018cites this paper
• Antibody Therapeutics in Oncology

  2016cites this paper
• to th e Proble m of Huma n Neoplasi a

  2016cites this paper
• Toxicities Associated with Antibody Drug Conjugates

  2015cites this paper
• State of melanoma: an historic overview of a field in transition.

  2014cites this paper
• Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.

  2014cites this paper
• A note from history: Landmarks in history of cancer, Part 6

  2013cites this paper
• Historical review of melanoma treatment and outcomes.

  2013cites this paper
• TRANSGENIC MICROALGAE AS GREEN CELL FACTORIES

  2013cites this paper
• Risks and untoward toxicities of antibody-based immunoconjugates.

  2012cites this paper
• Therapeutic Vaccines for Melanoma

  2012cites this paper
• Tumour Cell-Based Vaccines for the Treatment of Melanoma

  2012cites this paper
• Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities

  2012cites this paper
• Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.

  2011cites this paper
• Donald L. Morton, MD … A living legend in surgical oncology

  2011cites this paper
• Immunotherapy for Cutaneous Malignancy

  2011cites this paper
• fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

  2011cites this paper
• Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge

  2010cites this paper
• Novel therapeutics for the treatment of metastatic melanoma.

  2009cites this paper
• The immune reaction against malignant melanoma studied in a biopsy material.

  2009cites this paper
• Usage of cancer associated autoantibodies in the detection of disease

  2009cites this paper
• SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.

  2008cites this paper
• Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.

  2008cites this paper
• h4EMBRANE ANTIGENS OF HUMAN COLONIC CARCINOMA WITH A NEW ISOLATION METHOD AND NON-TUMORAL COLONIC MUCOSA : RESULTS OBTAINED

  2006cites this paper
• SOLUBLE MEMBRANE ANTIGENS OF H U M A N MALIGNANT MELANOMA CELLS

  2006cites this paper
• The treatment of melanoma with an emphasis on immunotherapeutic strategies.

  2006cites this paper
• Role of Melanoma-Associated Antigens

  2006cites this paper
• High Tech Trash: Digital Devices, Hidden Toxins, and Human Health

  2006cites this paper
• Immunoscintigraphy for cancer detection: “A thousand ills require a thousand cures”

  2005cites this paper
• Leukozyten-Adhärenz-Inhibition: Ein einfacher In-vitro-Test zum Nachweis tumorspezifischer Immunität und blockierender Serumfaktoren bei Kindern mit Malignomen

  2005cites this paper
• The evolution of antibodies into versatile tumor-targeting agents.

  2005cites this paper
• The concept of immunochemosurgery in gastric cancer

  2005cites this paper
• Therapeutic vaccines for melanoma: current status.

  2005cites this paper
• Inhibition of the arrest of hematogenously disseminated tumor cells

  2004cites this paper
• Human tumor-associated antigens identified by monoclonal antibodies

  2004cites this paper
• Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease free interval and survival

  2004cites this paper
• Preliminary results on the use of the humoral immune response as a serum marker in patients with bladder tumors

  2004cites this paper
• Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin

  2004cites this paper
• Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673)

  2004cites this paper
• Quantitative measurements of humoral immune response in mice to a FANFT induced bladder tumor

  2004cites this paper
• Immunologische Aspekte beim malignen Melanom

  2004cites this paper
• Mitogene aktivität von melanomextrakten in leukocytenkulturen

  2004cites this paper
• Peripheral Blood CD4+ T-Cell Response Before Postoperative Active Immunotherapy Correlates with Clinical Outcome in Metastatic Melanoma

  2004cites this paper
• Therapeutic vaccination with tumor cells that engage CD137

  2003cites this paper
• Immunotherapy of malignant melanoma.

  2003cites this paper
• CELL SURFACE ANTIGENS OF H U M A N MALIGNANT MELANOMA

  2003cites this paper
• Royal College of Radiologists Annual Undergraduate Essay Prize. Melanoma: the new smallpox? Can vaccines be used to treat melanoma?

  2002cites this paper
• Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma

  2002cites this paper
• One Hundred Citation Classics in General Surgical Journals

  2002cites this paper
• Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes

  2002cites this paper
• Evaluation of a Recombinant Antigen Enzyme-Linked Immunosorbent Assay (ELISA) in the Diagnostics of Antinuclear Antibodies (ANA) in Children with Rheumatic Disorders

  2002cites this paper
• A Case of Malignant Melanoma Associated with Vitiligo

  2000cites this paper
• Biologic therapy.

  2000cites this paper
• Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?

  2000cites this paper
• Natural and Induced Human Antibody Response to Cancer

  2000cites this paper
• Clinical implications of the new biology in the development of melanoma vaccines

  1999cites this paper
• Regulation of CR3 (CD11b/CD18)‐dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules

  1999cites this paper
• Vaccine therapy for patients with melanoma.

  1999cites this paper
• Regulation of CR 3 ( CD 11 b / CD 18 )-dependent natural killer ( NK ) cell cytotoxicity by tumour target cell MHC class I molecules

  1999cites this paper
• Vaccines and other adjuvant therapies for melanoma.

  1998cites this paper
• Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.

  1998cites this paper
• Adjuvant therapy for cutaneous malignant melanoma.

  1997cites this paper
• Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).

  1997cites this paper
• Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.

  1997cites this paper
• Current Status of Melanoma Vaccines

  1997cites this paper
• Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma

  1997cites this paper
• Update on active specific immunotherapy with melanoma vaccines

  1997cites this paper
• The role of adoptive immunotherapy in solid cancers.

  1997cites this paper
• Vaccine therapy for malignant melanoma

  1996cites this paper
• The role of immunotherapy in urologic malignancies.

  1996cites this paper
• [Future of malignant stage I melanoma. Immunology and immunotherapy].

  1995cites this paper
• The role of adjuvant therapy in melanoma management

  1995cites this paper
• Biologic treatment of human cancer.

  1995cites this paper
• Das maligne Melanom — Fortschritt durch Forschung

  1995cites this paper
• Grundlagen immunologischer Vorgänge beim Plattenepithelkarzinom im Kopf-Hals-Bereich — Diagnostik und Ursachen

  1995cites this paper
• Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.

  1995cites this paper
• Tumor gangliosides as targets for active specific immunotherapy of melanoma in man.

  1994cites this paper
• Response of primary oral malignant melanoma to interferon: report of two cases.

  1994cites this paper
• Characterization of spontaneous immunological regression in a histiocytoma .1. Role of NK cells and antitumor antibodies.

  1993cites this paper
• Polyvalent Melanoma Vaccine Improves Survival of Patients with Metastatic Melanoma a

  1993cites this paper
• Immune defects in patients with head and neck cancer.

  1993cites this paper
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

  1992cites this paper
• Appraisal of anti-idiotypic antibodies in the treatment of solid tumors in humans.

  1992cites this paper
• Immunotherapy for malignant melanoma with a tumor cell vaccine.

  1992cites this paper
• Possibilities for active immunotherapy of human cancer.

  1992cites this paper
• Melanoma: new biology; new therapy.

  1991cites this paper
• Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.

  1991cites this paper
• Characterization of a 90‐100 kDa tumor‐associated antigen in the sera of melanoma patients

  1990cites this paper
• Antimelanoma Antibodies for Therapy

  1990cites this paper
• Mouse Antibodies to Carcinomas

  1990cites this paper
• Clinical Implications of Human Melanoma-Associated Antigens

  1990cites this paper
• Monoclonal antibodies: clinical applications.

  1989cites this paper
• Monoclonal Antibody L/1C2 Reactive with a Human Carcinoma Associated Antigen

  1989cites this paper
• Active specific immunotherapy in malignant melanoma.

  1989cites this paper
• A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

  1989cites this paper
• Detection of a tumor‐associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1‐40F4) in enzyme immunoassay

  1989cites this paper
• Sunlight and melanomas.

  1988cites this paper